SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin versus placebo in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis. Conference call and webcast details are as follows: Live Conference CallDomestic Callers: (844) 873-0551International Callers: (602) 563-8472Passcode: 9393531 Live and Archived Webcast For the live or archived webcast, please visit the “Investors & Media” section of NGM’s website at https://ir.ngmbio.com/. The webcast will be archived for 30 days. Archived Conference Call Domestic Callers: (855) 859-2056International Callers: (404) 537-3406Passcode: 9393531The archived conference call will be available for 30 days. About NGM Biopharmaceuticals, Inc.NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. Visit us at www.ngmbio.com for more information. Investor Contact:Alex Schwartzir@ngmbio.com Media Contact:Liz Melonemedia@ngmbio.com